Finally, we show that in GBM with EGFR amplification (EGFRamp), long-term exposure to erlotinib induces adaptive tumor growth that involves MET pathway activation, supporting the use of a combination of both inhibitors to more effectively control GBM progression. Here, EGFR is linked to glioblastoma.